{"entity":{"id":"divarasib","kind":"drug","name":"Divarasib","aka":[],"tldr":"Divarasib is Roche's KRAS G12C pill, the first to beat the two approved KRAS drugs head-to-head (July 2026).","summary":"Covalent G12C inhibitor with ~5-20-fold greater potency than sotorasib/adagrasib in preclinical models; phase 1 ORR 53% in NSCLC. Krascendo 1 (vs sotorasib or adagrasib, previously treated NSCLC) met PFS and OS. Krascendo 2 tests divarasib + pembrolizumab ± chemotherapy first line. FDA orphan designation 2026; filing expected.","status":"phase-3","asOf":"2026-09-06","links":[{"label":"Roche Krascendo 1 release","url":"https://www.roche.com/media/releases/med-cor-2026-07-02"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","kras-g12c-nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["krascendo-1","nct07541170","nct06793215","nct05789082"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"GDC-6036","modality":"Small-molecule inhibitor (KRAS G12C)","mechanism":"Covalent KRAS G12C (OFF-state) inhibitor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/divarasib/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"trial":[{"id":"nct06793215","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","route":"/trials/nct06793215/"},{"id":"nct05789082","kind":"trial","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","route":"/trials/nct05789082/"},{"id":"nct07541170","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","route":"/trials/nct07541170/"},{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","route":"/trials/krascendo-1/"}],"biomarker":[{"id":"kras-g12c","kind":"biomarker","name":"KRAS G12C","route":"/biomarkers/kras-g12c/"}],"roadmap":[{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}],"pathway":[{"id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/"}]}}